Dashboard
Manage Tickers

SPRY ARS Pharmaceuticals, Inc.

Nasdaq ars-pharma.com


$ 9.24 $ -0.54 (-5.6 %)    

Friday, 24-Oct-2025 18:08:19 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 9.11
$ 9.67
$ 9.01 x 10
$ 9.26 x 5
$ 9.08 - $ 9.76
$ 9.08 - $ 18.90
1,923,973
na
900.31M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-29-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ars-pharmaceuticals-announces-opposition-division-of-the-european-patent-office-upholds-nasal-spray-epinephrine-patent
ARS Pharmaceuticals Announces Opposition D...
10/08/2025 14:14:08

SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical com...

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
10/03/2025 21:05:59

ars-pharmaceuticals-secures-up-to-250m-loan-facility-with-ra-capital-management-and-omers-life-sciences-for-neffy-commercialization
ARS Pharmaceuticals Secures Up To $250M Lo...
09/29/2025 20:07:25

ars-pharma-urges-fda-to-delay-approval-of-aquestives-allergic-reaction-treatment
ARS Pharma Urges FDA To Delay Approval Of ...
09/23/2025 16:01:54

ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardio...

ars-pharma-japanese-authority-pmda-grants-approval-for-neffy-1-mg-and-2-mg-doses-for-emergency-treatment-of-allergic-reactions-in-adults-and-children
ARS Pharma Japanese Authority PMDA Grants ...
09/19/2025 12:02:40

neffy 1 mg and 2 mg doses approved by Japanese regulatorsneffy offers a new delivery method for epinephrine in Japan for adults...

ars-pharma-shares-real-world-evidence-evaluating-clinical-performance-of-neffy-in-patients-experiencing-anaphylaxis-symptoms-during-oral-food-challenge-and-allergen-immunotherapy
ARS Pharma Shares Real-World Evidence Eval...
09/08/2025 12:03:12

Findings accepted for publication in the official journal of the American College of Allergy, Asthma and ImmunologyAbout 9 out ...

roth-capital-initiates-coverage-on-ars-pharmaceuticals-with-buy-rating-announces-price-target-of-40
Roth Capital Initiates Coverage On ARS Pha...
09/04/2025 17:46:38

Roth Capital analyst Jason Wittes initiates coverage on ARS Pharmaceuticals (NASDAQ:SPRY) with a Buy rating and announces Pr...

ars-pharmaceuticals-q2-eps-046-inline-sales-15717m-beat-13776m-estimate
ARS Pharmaceuticals Q2 EPS $(0.46), Inline...
08/13/2025 11:01:03

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.46) per share which met the analyst consensus estimate. This...

Core News & Articles
Earnings Scheduled For August 13, 2025
08/13/2025 08:32:30

earnings-outlook-for-ars-pharmaceuticals
Earnings Outlook For ARS Pharmaceuticals
08/12/2025 15:02:52

Core News & Articles
ARS Pharma Says U.K. MHRA Grants Approval ...
07/18/2025 13:27:39

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) livin...

jim-cramer-is-all-aboard-union-pacific-but-shows-no-love-for-orphan-drugs
Jim Cramer Is All Aboard Union Pacific, Bu...
06/12/2025 12:05:03

Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money...

ars-pharmaceuticals-q1-eps-035-misses-033-estimate-sales-797m-beat-748m-estimate
ARS Pharmaceuticals Q1 EPS $(0.35) Misses ...
05/14/2025 11:01:58

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of...

Core News & Articles
Earnings Scheduled For May 14, 2025
05/14/2025 08:32:23

ars-pharmaceuticalss-earnings-a-preview
ARS Pharmaceuticals's Earnings: A Preview
05/13/2025 15:01:34

ars-pharmaceuticals-entered-into-an-agreement-with-alk-abell-to-co-promote-neffy-epinephrine-nasal-spray-for-type-i-allergic-reactions-to-up-to-9000-pediatricians-for-an-upfront-of-145m
ARS Pharmaceuticals Entered Into An Agreem...
05/02/2025 12:06:46

Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million ...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
03/20/2025 17:06:07

jabil-posts-better-than-expected-earnings-joins-darden-restaurants-qxo-five-below-and-other-big-stocks-moving-higher-on-thursday
Jabil Posts Better-Than-Expected Earnings,...
03/20/2025 14:43:39

ars-pharmaceuticals-says-314m-in-cash-cash-equivalents-and-short-term-investments-at-year-end-2024-supporting-an-increased-investment-in-commercialization-in-2025-while-maintaining-an-operating-runway-of-at-least-three-years
ARS Pharmaceuticals Says $314M In Cash, Ca...
03/20/2025 11:04:51

ars-pharmaceuticals-q4-2024-gaap-eps-048-may-not-be-comparable-to-014-estimate-sales-8660m-may-not-be-comparable-to-1582m-estimate
ARS Pharmaceuticals Q4 2024 GAAP EPS $0.48...
03/20/2025 11:03:58

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION